Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population

Arthritis Care and Research

Volumn 66, Issue 12, 2014, Pages 1818-1827

  Terao, Chikashi ^a   Ohmura, Koichiro ^a   Ikari, Katsunori ^b   Kawaguchi, Takahisa ^a   Takahashi, Meiko ^a   Setoh, Kazuya ^a   Nakayama, Takeo ^a   Kosugi, Shinji ^a   Sekine, Akihiro ^a   Tabara, Yasuharu ^a   Taniguchi, Atsuo ^b   Momohara, Shigeki ^b   Yamanaka, Hisashi ^b   Yamada, Ryo ^a   Matsuda, Fumihiko ^a   Mimori, Tsuneyo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HLA DRB1 ANTIGEN; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGED; ALLELE; ANTIBODY PRODUCTION; ARTICLE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ASIAN CONTINENTAL ANCESTRY GROUP; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; JAPAN; MIDDLE AGED;

ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; EPITOPES; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 84912086745     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22385     Document Type: Article

References (45)

1. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
2. Renaudineau Y, Jamin C, Saraux A, Youinou P. Rheumatoid factor on a daily basis. Autoimmunity 2005;38:11-6.
3. Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528-34.
4. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21: 613-9.
5. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, Andre C, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995;122:169-73.
6. Yoshida H, Imafuku Y, Morita EO, Nagai T, Kato Y, Motegi S. Detection of antinuclear antibodies and their significance as disease markers. Rinsho Byori 1994;42:455-9. In Japanese.
7. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
8. Cammarata RJ, Rodnan GP, Fennell RH. Serum anti-gammaglobulin and antinuclear factors in the aged. JAMA 1967;199: 455-8.
9. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008;173:600-9.
10. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
11. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
12. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003;42:939-46.
13. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis 2004;63:1587-93.
14. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004;63: 1079-84.
15. Ohmura K, Terao C, Maruya E, Katayama M, Matoba K, Shimada K, et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 2010;49:2298-304.
16. Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W, et al. Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum 2002;47:403-7.
17. Morgan AW, Thomson W, Martin SG, Yorkshire Early Arthritis Register Consortium, Carter AM, UK Rheumatoid Arthritis Genetics Consortium, et al. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibodypositive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum 2009;60: 2565-76.
18. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69:70-81.
19. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 2012;44:511-6.
20. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
21. Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012;345:e5244.
22. Van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993;32: 546-9.
23. Jonsson T, Thorsteinsson J, Valdimarsson H. Does smoking stimulate rheumatoid factor production in non-rheumatic individuals? APMIS 1998;106:970-4.
24. Dequeker J, van Noyen R, Vandepitte J. Age-related rheumatoid factors: incidence and characteristics. Ann Rheum Dis 1969;28:431-6.
25. Waller M, Toone EC, Vaughan E. Study of rheumatoid factor in a normal population. Arthritis Rheum 1964;7:513-20.
26. Yoshimura K, Nakayama T, Sekine A, Matsuda F, Kosugi S, Sugino Y, et al. Prevalence of postmicturition urinary incontinence in Japanese men: comparison with other types of incontinence. Int J Urol 2013;20:911-6.
27. Terao C, Ikari K, Ohmura K, Suzuki T, Iwamoto T, Takasugi K, et al. Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLADRB1∗ 09:01. Ann Rheum Dis 2012;71:1095-7.
28. Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, et al. A large-scale association study identified multiple HLADRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Ann Rheum Dis 2011;70:2134-9.
29. Terao C, Ohmura K, Ikari K, Kochi Y, Maruya E, Katayama M, et al. ACPA-negative RA consists of two genetically distinct subsets based on RF positivity in Japanese. PLoS One 2012; 7:e40067.
30. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64: 2319-27.
31. Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, Nelson MR, et al. Multi-population classical HLA type imputation. PLoS Comput Biol 2013;9:e1002877.
32. Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y, et al. The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet 2011;20: 2680-5.
33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
34. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006;8:R133.
35. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)- restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
36. Tasliyurt T, Kisacik B, Kaya SU, Yildirim B, Pehlivan Y, Kutluturk F, et al. The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern Turkey. Rheumatol Int 2013;33:939-42.
37. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women: incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum 1991;34:1502-7.
38. Palosuo T, Tilvis R, Strandberg T, Aho K. Filaggrin related antibodies among the aged. Ann Rheum Dis 2003;62:261-3.
39. Haj Hensvold A, Magnusson PK, Joshua V, Hansson M, Israelsson L, Ferreira R, et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2013. E-pub ahead of print.
40. Lundstrom E, Kallberg H, Smolnikova M, Ding B, Ronnelid J, Alfredsson L, et al. Opposing effects of HLA-DRB1∗13 alleles on the risk of developing anti-citrullinated protein antibodypositive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60:924-30.
41. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 1993;20:2005-9.
42. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48: 2741-9.
43. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
44. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
45. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:R303-8.